Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.
21 CFR 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.
21 CFR 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity., “Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible…”, is a CFR section of 21 CFR Part 314, Subpart H—Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses; in force.
https://ontology.bommaritollc.com/id/01a0f094-c4e5-76cd-b2d9-17a3b02eef62
Elsewhere
Facts
| adms:identifier | |
| prov:wasDerivedFrom | |
| schema:isPartOf | |
| schema:legislationIdentifier | 21 CFR 314.510 |
| schema:legislationJurisdiction | |
| schema:legislationLegalForce | |
| schema:legislationType | |
| schema:name | Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidityen |
| schema:url | |
| skos:prefLabel | 21 CFR 314.510 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.en |